Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor

European Journal of Pharmacology

Volumn 714, Issue 1-3, 2013, Pages 359-365

  Ashby, Charles R ^a   Kehne, John H ^b   Bartoszyk, Gerd D ^c   Renda, Matthew J ^d   Athanasiou, Maria ^e   Pierz, Kerri A ^f   Seyfried, Christoph A ^f,g  

^a ST JOHN'S UNIVERSITY   (United States)

^b Translational Neuropharmacology Consulting   (United States)

^c Merck Serono GmbH   (Germany)

^d PGxHealth LLC   (United States)

^e Athanasiou Consulting   (United States)

^f Forest Laboratories Inc ^*  (Germany)

^g MERCK KGAA   (Germany)

Author keywords

5 HT reuptake inhibitor; Antidepressant; In vivo electrophysiology; PCA model; Vilazodone

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CHLORAMPHETAMINE; CITALOPRAM; FENFLURAMINE; FLUOXETINE; PAROXETINE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VILAZODONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG DOSE COMPARISON; DRUG POTENCY; EX VIVO STUDY; HYPOTHALAMUS; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SEROTONIN BRAIN LEVEL; SEROTONIN UPTAKE; SEROTONINERGIC NERVE CELL;

5-HT REUPTAKE INHIBITOR; 5-HT(1A) RECEPTOR PARTIAL AGONIST; ANTIDEPRESSANT; IN VIVO ELECTROPHYSIOLOGY; PCA MODEL; VILAZODONE;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BENZOFURANS; BRAIN STEM; DRUG PARTIAL AGONISM; ELECTROPHYSIOLOGICAL PROCESSES; FENFLURAMINE; INDOLES; MALE; P-CHLOROAMPHETAMINE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONERGIC NEURONS; SEROTONIN RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 84885480792     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.07.014     Document Type: Article

References (34)

1. Aghajanian, G.K., Haigler, H.J., 1974. Mode of action of LSD on serotonergic neurons. Adv. Biochem. Psychopharmacol. 10, 167-177.
2. Bartoszyk, G.D., Barber, A., Böttcher, H., Greiner, H.E., Leibrock, J., Martinez, J.M., Seyfried, C.A., 1996. Pharmacological Profile of the Mixed 5-HT Reuptake Inhibitor/5-HT1A Agonist EMD 68843 [Abstract]. Poster Presented at: The Society for Neuroscience Annual Meeting; November 16-21; Washington D.C.
3. Bartoszyk, G.D., Hegenbart, R., Ziegler, H., 1997. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur. J. Pharmacol. 322, 147-153. (Pubitemid 27122887)
4. Berger, U.V., Gu, X.F., Azmitia, E.C., 1992. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol. 215, 153-160.
5. Blier, P., Ward, N.M., 2003. Is there a role for 5-HT1A agonists in the treatment of depression? Biol. Psychiatry 53, 193-203. (Pubitemid 36135929)
6. Charney, D.S., 1998. Monoamine dysfunction and the pathophysiology and treatment of depression. J. Clin. Psychiatry 59 (Suppl. 14), 11-14. (Pubitemid 28462383)
7. Cox, R.F., Meller, E., Waszczak, B.L., 1993. Electrophysiological evidence for a large receptor reserve for inhibition of dorsal raphe neuronal firing by 5-HT1A agonists. Synapse 14, 297-304. (Pubitemid 23231008)
8. Czachura, J.F., Rasmussen, K., 2000. Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat. Naunyn Schmiedebergs Arch. Pharmacol. 362, 266-275.
9. Dawson, L.A., Watson, J.M., 2009. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci. Ther. 15, 107-117.
10. Fuller, R.W., 1980. Mechanism by which uptake inhibitors antagonize p-chloro-amphetamine-induced depletion of brain serotonin. Neurochem. Res. 5, 241-245. (Pubitemid 10134134)
11. Gammans, R.E., Stringfellow, J.C., Hvizdos, A.J., Seidehamel, R.J., Cohn, J.B., Wilcox, C. S., Fabre, L.F., Pecknold, J.C., Smith, W.T., Rickels, K., 1992. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsycho-biology 25, 193-201.
12. Glowinski, J., Iversen, L.L., 1966. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J. Neurochem. 13, 655-669.
13. Heinrich, T., Bottcher, H., Gericke, R., Bartoszyk, G.D., Anzali, S., Seyfried, C.A., Greiner, H.E., Van Amsterdam, C., 2004. Synthesis and structure-activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J. Med. Chem. 47, 4684-4692. (Pubitemid 39195559)
14. Heisler, L.K., Chu, H.M., Brennan, T.J., Danao, J.A., Bajwa, P., Parsons, L.H., Tecott, L.H., 1998. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc. Natl. Acad. Sci. USA 95, 15049-15054. (Pubitemid 29003754)
15. Hewitt, N.J., Buhring, K.U., Dasenbrock, J., Haunschild, J., Ladstetter, B., Utesch, D., 2001. Studies comparing in vivo: in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug. Metab. Dispos. 29, 1042-1050. (Pubitemid 32605921)
16. Hughes, Z.A., Starr, K.R., Langmead, C.J., Hill, M., Bartoszyk, G.D., Hagan, J.J., Middlemiss, D.N., Dawson, L.A., 2005. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur. J. Pharmacol. 510, 49-57. (Pubitemid 40312389)
17. Hughes, Z.A., Starr, K.R., Scott, C.M., Newson, M.J., Sharp, T., Watson, J.M., Hagan, J.J., Dawson, L.A., 2007. Simultaneous blockade of 5-HT1A/B receptors and 5-HT transporters results in acute increases in extracellular 5-HT in both rats and guinea pigs: in vivo characterization of the novel 5-HT1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B. Psychopharmacology (Berl.) 192, 121-133. (Pubitemid 46673892)
18. Khan, A., 2009. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin. Invest. Drugs 18, 1753-1764.
19. Khan, A., Cutler, A.J., Kajdasz, D.K., Gallipoli, S., Athanasiou, M., Robinson, D.S., Whalen, H., Reed, C.R., 2011. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J. Clin. Psychiatry 72, 441-447.
20. Klemenhagen, K.C., Gordon, J.A., David, D.J., Hen, R., Gross, C.T., 2006. Increased fear response to contextual cues in mice lacking the 5-HT1A receptor. Neuropsy-chopharmacology 31, 101-111. (Pubitemid 43250945)
21. Laughren, T.P., Gobburu, J., Temple, R.J., Unger, E.F., Bhattaram, A., Dinh, P.V., Fossom, L., Hung, H.M., Klimek, V., Lee, J.E., Levin, R.L., Lindberg, C.Y., Mathis, M., Rosloff, B.N., Wang, S.J., Wang, Y., Yang, P., Yu, B., Zhang, H., Zhang, L., Zineh, I., 2011. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J. Clin. Psychiatry 72, 1166-1173.
22. Meller, E., Bohmaker, K., 1994. Differential receptor reserve for 5-HT1A receptor-mediated regulation of plasma neuroendocrine hormones. J Pharmacol. Exp. Ther. 271, 1246-1252. (Pubitemid 24382629)
23. Meller, E., Goldstein, M., Bohmaker, K., 1990. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists. Mol. Pharmacol. 37, 231-237. (Pubitemid 20082987)
24. Nutt, D.J., 2002. The neuropharmacology of serotonin and noradrenaline in depression. Int. Clin. Psychopharmacol. 17 (Suppl. 1), S1-12.
25. Page, M.E., Cryan, J.F., Sullivan, A., Dalvi, A., Saucy, B., Manning, D.R., Lucki, I., 2002. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2- carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J. Pharmacol. Exp. Ther. 302, 1220-1227. (Pubitemid 34920246)
26. Parsey, R.V., Oquendo, M.A., Ogden, R.T., Olvet, D.M., Simpson, N., Huang, Y.Y., Van Heertum, R.L., Arango, V., Mann, J.J., 2006. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol. Psychiatry 59, 106-113. (Pubitemid 43117499)
27. Reed, C.R., Kajdasz, D.K., Whalen, H., Athanasiou, M.C., Gallipoli, S., Thase, M.E., 2012. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr. Med. Res. Opin. 28, 27-39.
28. Riad, M., Watkins, K.C., Doucet, E., Hamon, M., Descarries, L., 2001. Agonist-induced internalization of serotonin-1a receptors in the dorsal raphe nucleus (auto-receptors) but not hippocampus (heteroreceptors). J. Neurosci. 21, 8378-8386. (Pubitemid 33051436)
29. Rickels, K., Athanasiou, M., Robinson, D.S., Gibertini, M., Whalen, H., Reed, C.R., 2009. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 70, 326-333.
30. Roberts, C., Hagan, J.J., Bartoszyk, G.D., Kew, J.N., 2005. Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus. Eur. J. Pharmacol. 517, 59-63. (Pubitemid 40910253)
31. Robinson, D.S., Rickels, K., Feighner, J., Fabre Jr., L.F., Gammans, R.E., Shrotriya, R.C., Alms, D.R., Andary, J.J., Messina, M.E., 1990. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J. Clin. Psychopharmacol. 10, 67S-76S. (Pubitemid 20212933)
32. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Stewart, J.W., Nierenberg, A.A., Thase, M. E., Ritz, L., Biggs, M.M., Warden, D., Luther, J.F., Shores-Wilson, K., Niederehe, G., Fava, M., 2006. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 354, 1231-1242.
33. Seyfried, C.A., Adam, G., Greve, T., 1986. An automated direct-injection HPLC-method for the electrochemical/fluorimetric quantitation of monoamines and related compounds optimized for the screening of large numbers of animals. Biomed. Chromatogr. 1, 78-88.
34. Seyfried, C.A., Greiner, H.E., Haase, A.F., 1989. Biochemical and functional studies on EMD 49, 980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems. Eur. J. Pharmacol. 160, 31-41. (Pubitemid 19044826)